Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (5 quarters reported)
$127M in Q4 2019 → $138M now. Hover for any quarter.
As reported for the quarter ended September 30, 2021. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| TD Tandem Diabetes, Inc. | 86.2% | Unchanged | 1,000,000 | $119M |
| Karyopharm Therapeutics, Inc. | 9.5% | Unchanged | 2,263,006 | $13.2M |
| Calithera Biosciences, Inc. | 3.8% | Unchanged | 2,426,702 | $5.29M |
| Mereo Biopharma Group PLC | 0.4% | Unchanged | 256,734 | $621K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 4 quarters.
quarter ended September 30, 2021 · filed November 15, 2021
No position changes this quarter.
quarter ended June 30, 2021 · filed August 12, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Senseonics Holdings, Inc. | Exited | −9,846,294 | −$26M | — |
quarter ended March 31, 2021 · filed May 17, 2021
No position changes this quarter.
quarter ended December 31, 2020 · filed February 08, 2021
No position changes this quarter.
Loading...
